Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02582801

Enrollment

Registered

2015-10-21

Start date

2015-10-31

Completion date

2019-09-30

Last updated

2019-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

PET/CT, Alfatide Ⅱ, breast cancer

Brief summary

18F-Alfatide Ⅱ PET/CT in breast cancer patients

Detailed description

The investigators aim to assess the clinical application of 18F-Alfatide Ⅱ PET/CT in the diagnosis and treatment response monitoring of breast cancer.

Interventions

DRUG18F-Alfatide Ⅱ PET/CT

Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* The patients have been suspected or diagnosed with breast cancer and they have not received any treatment; It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion criteria

* Pregnancy or nursing mothers; Those patients accompanied by other serious diseases such as cardiac functional insufficiency, hepatic and renal function insufficiency.

Design outcomes

Primary

Measure	Time frame	Description
Maximum standardized uptake value (SUVmax)	1 day	the uptake intensity of lesions

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026